SCHEMBL10035571

SCHEMBL10035571

COc1cc2c(cc1OC)CN(CCCNS(=O)(=O)c1sc3ccc(Cl)cc3c1C)CC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.52
DRD2 P14416 7/20 0.52
HTR7 P34969 6/20 0.52
HTR2A P28223 5/20 0.52
DRD3 P35462 5/20 0.52
HTR1A P08908 4/20 0.52
HTR2C P28335 4/20 0.52
HTR2B P41595 3/20 0.52
HTR1D P28221 3/20 0.52
HTR1B P28222 3/20 0.52
ADRA1B P35368 3/20 0.52
HTR4 Q13639 3/20 0.52
HTR1E P28566 1/20 0.52
HTR1F P30939 1/20 0.52
HRH1 P35367 1/20 0.51
DRD1 P21728 2/20 0.47
DRD4 P21917 2/20 0.47
TMEM97 Q5BJF2 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2139362 0.99 DRD2 (0.53) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL8983356 0.97 DRD2 (0.53) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL10035547 0.88 HTR7 (0.55) HTR6DRD2HTR7HTR2ADRD3
Hydrochloric Acid SCHEMBL2135275 0.87 HTR7 (0.54) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL8979950 0.85 HTR7 (0.56) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL8982971 0.84 HTR7 (0.55) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL8980063 0.84 HTR7 (0.55) HTR6DRD2HTR7HTR2ADRD3
Hydrochloric Acid SCHEMBL5417558 0.84 HTR7 (0.54) HTR6DRD2HTR7HTR2ADRD3
SCHEMBL13878296 0.81 DRD2 (0.50) DRD2HTR7HTR2ADRD3HTR1A
SCHEMBL10035558 0.81 HTR7 (0.56) HTR6DRD2HTR7HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148397-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-04-03 US disclosed
US-8148397-B2 5-HT7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-04-03 US disclosed
US-20090088450-A1 5-ht7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-04-02 US disclosed
US-20090088450-A1 5-ht7 receptor antagonists LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-04-02 US disclosed
US-7211584-B2 5-HT7 receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-05-01 US disclosed
US-7211584-B2 5-HT7 receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088450-A1 5-ht7 receptor antagonists HTR7, HTR1A, HTR5A HTR6 7/4885DRD2 42/4885HTR7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.